Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.72 |
| ▸ | JAK2 | O60674 | 2/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.60 |
| ▸ | JAK1 | P23458 | 1/20 | 0.57 |
| ▸ | BRD2 | P25440 | 1/20 | 0.57 |
| ▸ | JAK3 | P52333 | 1/20 | 0.57 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.57 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1606982 | 0.91 | BRD4 (0.69) | BRD4 | |
| SCHEMBL1115595 | 0.90 | BRD4 (0.55) | BRD4JAK2FLT3JAK1JAK3 | |
| SCHEMBL1896619 | 0.89 | BRD4 (0.60) | BRD4JAK2FLT3JAK1BRD2 | |
| SCHEMBL1606964 | 0.86 | BRD4 (0.60) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL18757687 | 0.84 | BRD4 (1.00) | BRD4JAK2FLT3JAK1BRD2 | |
| SCHEMBL4974359 | 0.84 | JAK3 (0.54) | BRD4JAK2FLT3JAK1JAK3 | |
| SCHEMBL1607609 | 0.82 | BRD4 (0.60) | BRD4JAK2 | |
| SCHEMBL1606788 | 0.82 | BRD4 (0.68) | BRD4JAK2FLT3JAK1BRD2 | |
| SCHEMBL17526072 | 0.81 | BRD4 (1.00) | BRD4JAK2FLT3JAK1BRD2 | |
| SCHEMBL4970287 | 0.81 | BRD4 (0.49) | BRD4JAK2FLT3JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | claimed |
| US-7947698-B2 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | BRD4 2500/4885JAK2 3/4885FLT3 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.